Prospectus
Disclaimer
You have selected a web site with information that is not intended to be published, published or distributed, directly or indirectly, in or to the United States, Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore, South Korea, Switzerland, Canada or any other jurisdiction where such action may constitute violation of local securities laws or regulations.
You have selected a web site with information that is not intended to be published, published or distributed, directly or indirectly, in or to the United States, Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore, South Korea, Switzerland, Canada or any other jurisdiction where such action may constitute violation of local securities laws or regulations.
Disclaimer
You have selected a web site with information that is not intended to be published, published or distributed, directly or indirectly, in or to the United States, Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore, Canada or any other jurisdiction where such action may constitute violation of local securities laws or regulations. By clicking "Yes, I accept" below you are agreeing to the terms of access to this website.
The offer to subscribe for shares in Enzymatica AB (publ) in accordance with the terms of the prospectus is not aimed at persons whose participation in the offer requires additional prospectus, registration measures or other measures than those that follow from Swedish law. The prospectus and other documents relating to the offer may not be distributed in any country where such distribution or the offer requires additional measures than those specified in the previous sentence or contravene rules in such country. Neither subscription rights, paid subscription shares (BTAs) nor newly issued shares have been registered or will be registered in accordance with the United States Securities Act of 1933 in force, or under applicable law in Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore or Canada and thus may not be offered or transferred, directly or indirectly, to a resident of any of these countries. The notification of subscription of shares in contravention of the above may be considered invalid and be disregarded.
Disputes arising from the offer, the contents of the prospectus and related legal matters shall be decided exclusively by the Swedish court. Swedish law applies exclusively to the prospectus and to the offer according to the prospectus.
In order to be entitled to access the information on the following web site, you must, if you access the following web site, have confirmed and stated that (i) you have read and accept the terms and conditions stated above and (ii) you are not in the US, Australia, Japan, New Zealand, South Africa, Hong Kong, Singapore or Canada
By clicking "Yes, I accept" below you are agreeing to the terms of access to this website.
Tillgång till informationen på denna del av webbplatsen är begränsad och får inte publiceras, distribueras eller offentliggöras, direkt eller indirekt, helt eller delvis, i eller till Australien,Japan, Kanada, USA (inklusive dess territorium och ägor, samt delstater i USA och Columbiadistriktet (“USA”)), Sydafrika eller någon annan jurisdiktion där ett en sådant agerande kan bryta mot lokal värdepapperslagstiftning i sådan jurisdiktion.
Prospectus
Rights issue 2018
November 1, 2018
Documents
English summary regarding rights issuePress release – Prospectus for Enzymatica’s rights issue with preferential rights for existing shareholders published
Application form – for subscription of shares without the use of subscription rights
Special application form – for subscription of shares using subscription rights